机构：[1]Capital Med Univ, Xuanwu Hosp, Dept Intens Care Med, Beijing, Peoples R China首都医科大学宣武医院[2]Capital Med Univ, Xuanwu Hosp, Dept Pharm, Beijing, Peoples R China首都医科大学宣武医院[3]Capital Med Univ, Xuanwu Hosp, Dept Urol Surg, Beijing, Peoples R China首都医科大学宣武医院
Polymyxin B (PMB) and colistin are bactericidal polypeptide antibiotics discovered in 1947 and 1949 for the treatment of gram-negative bacterial infections. Polymyxin was used clinically in the 1950s, but it was gradually replaced by other antibiotics in the 1980s because of its high nephrotoxicity and neurotoxicity. In recent years, the increase of multidrug-resistant negative bacteria has led to the resurgence of polymyxin use. However, its side effects are not clear. Respiratory paralysis caused by PMB-related neuromuscular blockade is a rare but potentially fatal effect. We report a case of respiratory paralysis probably caused by polymyxin B infusion.
基金：
National Key Research and Development Program of China; [2020YFC2005403]
第一作者机构：[1]Capital Med Univ, Xuanwu Hosp, Dept Intens Care Med, Beijing, Peoples R China
通讯作者：
推荐引用方式(GB/T 7714)：
Ning Yachan,Chu Yanqi,Wu You,et al.Case Report: Respiratory paralysis associated with polymyxin B therapy[J].FRONTIERS IN PHARMACOLOGY.2022,13:doi:10.3389/fphar.2022.963140.
APA：
Ning, Yachan,Chu, Yanqi,Wu, You,Huang, Ying,Wang, Chunmei&Jiang, Li.(2022).Case Report: Respiratory paralysis associated with polymyxin B therapy.FRONTIERS IN PHARMACOLOGY,13,
MLA：
Ning, Yachan,et al."Case Report: Respiratory paralysis associated with polymyxin B therapy".FRONTIERS IN PHARMACOLOGY 13.(2022)
医学